CP-870893

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCP-870893
Drug Alias NameCP-870893
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 agonists
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsPancreatic NeoplasmsMelanomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncF. Hoffmann-La Roche LtdH Lee Moffitt Cancer Center & Research Institute +[4] 
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsMelanomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A